Target(s)
- Bayer Aktiengesellschaft’s animal health business
Summary
Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. In Australia, this includes:
- pharmaceuticals, such as parasiticides and antimicrobials and analgesics,
- specialty products, which include immunomodulators,
- nutritionals, including vitamins, feed supplements and feed additives, and
- other products including disinfectants.
Market inquiries
Submissions are invited from interested parties regarding the proposed acquisition. The closing date for submissions is 3 February 2020.
Submissions should be forwarded electronically (preferably in PDF format) to mergers@accc.gov.au with the title: "Submission re: Elanco/Bayer AG Animal Health - attention Alex Reed." Alternatively submissions may be mailed to the Merger Investigations Branch, ACCC, GPO Box 3131 Canberra ACT 2601.
Following 3 February 2020, queries regarding the ACCC's review may be addressed to Alex Reed at mergers@accc.gov.au.
For more details, please refer to the market inquiries letter below.
ACCC correspondence
Timeline
| Date | Event |
|---|---|
| 20/12/2019 | ACCC commenced informal review under the Informal Merger Review Process Guidelines. |
| 03/02/2020 | Closing date for submissions from interested parties. |
| 12/03/2020 | Proposed date for announcement of ACCC’s findings (as outlined in the Informal Merger Review Process Guidelines, this may be a final decision or release of a Statement of Issues). |
Project staff
- Alex Reed